<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25076440</article-id>
      <article-id pub-id-type="pmc">4131825</article-id>
      <article-id pub-id-type="publisher-id">S0036-46652014000400016</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652014000400016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO
INTRALESIONAL MEGLUMINE ANTIMONIATE</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Resolu&#xE7;&#xE3;o de leishmaniose cut&#xE2;nea ap&#xF3;s eczema agudo devido a antimoniato
de meglumina intralesional</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcellos</surname>
            <given-names>Erica de Camargo Ferreira e</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">(1)</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pimentel</surname>
            <given-names>Maria In&#xEA;s Fernandes</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">(1)</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Valete-Rosalino</surname>
            <given-names>Cl&#xE1;udia Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">(1)</xref>
          <xref ref-type="aff" rid="aff2">(2)</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Madeira</surname>
            <given-names>Maria de F&#xE1;tima</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">(1)</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schubach</surname>
            <given-names>Armando de Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">(1)</xref>
          <xref ref-type="aff" rid="aff3">(3)</xref>
          <xref ref-type="aff" rid="aff4"/>
        </contrib>
        <aff id="aff1"><label>(1)</label> Leishmaniasis Surveillance Laboratory, Evandro Chagas Clinical
Research Institute, Oswaldo Cruz Foundation, Rio de Janeiro, RJ,
<country>Brazil</country></aff>
        <aff id="aff2"><label>(2)</label> Otorhinolaryngology and Ophthalmology Department, Rio de Janeiro
Federal University, Rio de Janeiro, RJ, <country>Brazil</country></aff>
        <aff id="aff3"><label>(3)</label> Productivity scholarship from Scientific and Technology National
Council (CNPq), Bras&#xED;lia, <country>Brazil</country></aff>
        <aff id="aff4">Our State Scientist from Carlos Chagas Filho Foundation for the Research
Support in Rio de Janeiro State (FAPERJ)</aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> &#xC9;rica de Camargo Ferreira e Vasconcellos, Av. Brasil
4365, Manguinhos, 21040-360 Rio de Janeiro, RJ, Brasil. Phone: <phone>+55 21
3865-9541</phone>. E-mail: <email>erica.vasconcellos@ipec.fiocruz.br</email></corresp>
        <fn fn-type="conflict">
          <p>
<bold>CONFLICT OF INTEREST</bold> There is no conflict of interest regarding any
of the authors.</p>
        </fn>
        <fn fn-type="com">
          <p><bold>AUTHORS AND CONTRIBUTORS</bold> &#xC9;rica de Camargo Ferreira e Vasconcellos:
literature search, data collection, figures, writing. Maria In&#xEA;s Fernandes
Pimentel: literature search, data collection, figures, writing. Cl&#xE1;udia Maria
Valete-Rosalino: patient assistance (otorhinolaryngological), writing. Maria de
F&#xE1;tima Madeira: patient assistance (laboratorial diagnosis and species
characterization), writing. Armando de Oliveira Schubach: literature search,
figures, patient assistance (dermatological), writing.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2014</year>
      </pub-date>
      <volume>56</volume>
      <issue>4</issue>
      <fpage>361</fpage>
      <lpage>362</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="para1">We report a case of a 42 year-old female, who came to a leishmaniasis
reference center in Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis
lesion in the right forearm. Treatment with low-dose intramuscular meglumine
antimoniate (MA) (5 mg Sb<sup>5+</sup>/kg/day) was initiated, with improvement after
28 days, although with the development of generalized eczema. After 87 days, the
lesion worsened. Patient refused treatment with amphotericin B. MA was then
infiltrated in the lesion, in two sessions, resulting in local eczema, with bullae
formation; however, twenty days after, both the ulcer and eczema receded.
Intralesional administration of MA should be used carefully when previous cutaneous
hypersensitivity is detected.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p id="para2">Relatamos caso de paciente de 42 anos atendida em centro de refer&#xEA;ncia em
leishmanioses no Rio de Janeiro, Brasil, apresentando les&#xE3;o de leishmaniose cut&#xE2;nea
no antebra&#xE7;o direito. Iniciado tratamento com baixa dose de antimoniato de meglumina
(AM) intramuscular (5 mg Sb<sup>5+</sup>/kg/dia), houve melhora ap&#xF3;s 28 dias, por&#xE9;m
com desenvolvimento de eczema generalizado. Ap&#xF3;s 87 dias, notou-se piora da les&#xE3;o. A
paciente recusou o tratamento com anfotericina B. Infiltrou-se AM na les&#xE3;o em duas
sess&#xF5;es, resultando em eczema local com bolhas. Entretanto, 20 dias depois, tanto a
&#xFA;lcera quanto o eczema regrediram. A administra&#xE7;&#xE3;o intralesional do AM deve ser
utilizada com cautela em pacientes com hipersensibilidade cut&#xE2;nea a este f&#xE1;rmaco.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Cutaneous leishmaniasis</kwd>
        <kwd>Therapy</kwd>
        <kwd>Intralesional</kwd>
        <kwd>Meglumine antimoniate</kwd>
        <kwd>Eczema</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="0"/>
        <ref-count count="7"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>CASE REPORT</title>
      <p id="para3">American tegumentary leishmaniasis (ATL) is an infectious disease caused by
protozoa of <italic>Leishmania</italic> genus, transmitted by female sandflies
(Phlebotominae). Few medications are efficient in its treatment, among them meglumine
antimoniate (MA). Due to the difficulties linked to the administration of MA, less toxic
alternative therapies with low doses or intralesional injections (IL) of MA have been studied<sup><xref rid="B05" ref-type="bibr">5</xref>,<xref rid="B06" ref-type="bibr">6</xref></sup>. We report a case of a patient who presented resolution of cutaneous
leishmaniasis (CL) after development of acute eczema in the site of the injection of
MA.</p>
      <p id="para4">A 42 year-old white female, who signed a free informed consent form, came to
the Leishmaniasis Surveillance Laboratory, Evandro Chagas Clinical Research Institute,
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, presenting a CL lesion in the right
forearm for 45 days. Imprint of the lesion showed amastigotes parasites, and
<italic>Leishmania (Viannia) braziliensis</italic> was identified from the culture of
a fragment of the lesion obtained through biopsy. Mucosal lesions were not seen in fiber
optic otorhinolaryngological examination of the upper airways and digestive tract.
Treatment with low-dose intramuscular (IM) MA - 5 mg Sb<sup>5+</sup> per kilogram per
day - was initiated (Aventis, S&#xE3;o Paulo, Brazil). After a 28-day treatment, she
improved. However, she presented generalized eczema, treated with oral
dexclorpheniramine and dexametasone ointment. After 87 days, the ulcer worsened (<xref ref-type="fig" rid="f01">Fig. 1A</xref>). The second choice drug, amphotericin B
desoxycolate, was offered to the patient, but she refused to be hospitalized and
reported difficulties in going to the hospital three times a week to receive the
medication in a day-hospital regimen. Alternative drugs such as pentamidine and
liposomal amphotericin B were not available. Treatment was started with 7 mL of MA,
without any diluents, injected into the lesion edge until its whole base got
infiltrated. She developed moderate local eczema. Oral dexchlorpheniramine was
prescribed and the ulcer improved. After 13 days, a second IL MA injection was made,
with 5 mL of this drug, and the eczema worsened, with bullae formation (<xref ref-type="fig" rid="f01">Fig. 1B</xref>); however, twenty days after, both ulcer and
eczema receded (<xref ref-type="fig" rid="f01">Fig. 1C</xref>).</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Fig. 1 -</label><caption><title>Lesion's follow up: <bold>A -</bold> Ulcerated lesion, before the first
intralesional infiltration, measuring 20 x 10 mm, with infiltrated erythematous
borders, partially covered by crusts and with an epithelialized center of about
5 mm. <bold>B</bold> - Edema of the forearm and hand, after the second
intralesional infiltration of the lesion with meglumine antimoniate.
Infiltration, erythema and coalescing vesicles, turning into larger bubbles of
up to 35 mm. <bold>C</bold> - Atrophic scar, with erythema, residual
hyperpigmentation on the spot where the biggest bubble was located (49 days
after the second intralesional meglumine antimoniate).</title></caption><graphic xlink:href="0036-4665-rimtsp-56-04-361-gf01"/></fig>
</p>
      <p id="para5">IL way of administration is a viable alternative to systemic MA in older
people or in conditions in which systemic treatment is not tolerated, due to its
efficacy and infrequent, slight to moderate adverse events<sup><xref rid="B05" ref-type="bibr">5</xref>,<xref rid="B06" ref-type="bibr">6</xref></sup>. Local therapy was considered unsuitable for the treatment of New World cutaneous
leishmaniasis caused by <italic>L. (V.) braziliensis</italic> or <italic>L. (V.)
panamensis</italic> because of the potential risk of mucosal metastasis; however, as
systemic treatment does not guarantee prevention of later mucocutaneous leishmaniasis,
which is found in less than 5% of the cases, local treatments should be explored. It is
now considered acceptable to use local therapy in selected cases of New World cutaneous
leishmaniasis. The World Health Organization states that in patients with mild disease
or with comorbid conditions, treatments safer than systemic therapy should be preferred,
even if the level of evidence for efficacy is weak<sup><xref rid="B07" ref-type="bibr">7</xref></sup>.</p>
      <p id="para6">ASTE <italic>et al.</italic> (1998) had a successful experience with this
local therapy, with 11% of the patients presenting mild reactions, such as erythema or
pruritus, without systemic adverse effects. Patients didn't need to interrupt the treatment<sup><xref rid="B01" ref-type="bibr">1</xref></sup>.</p>
      <p id="para7">CORDOBA <italic>et al.</italic> (2012) described a series of 70 patients with
cutaneous leishmaniasis, treated with weekly intralesional infiltrations of MA
(Glucantime&#xAE;). Nine of them developed infiltrated itchy erythematous and vesiculous
plaques at the injection sites. After cutaneous tests, they concluded that type IV
hypersensitivity could be involved in the mechanism of the cutaneous reaction<sup><xref rid="B03" ref-type="bibr">3</xref></sup>.</p>
      <p id="para8">Some other diseases have been occasionally treated with local drugs that
induce hypersensitivity reactions; resolution of warts with dinitrochlorobenzene (DNCB)
is well documented<sup><xref rid="B04" ref-type="bibr">4</xref></sup>. In an animal model with guinea pigs, DNCB inhibited the development of
leishmaniasis cutaneous lesions, but only when applied in the infection sites<sup><xref rid="B02" ref-type="bibr">2</xref></sup>.</p>
      <p id="para9">Probably, hypersensitivity to MA was involved in the resolution of the lesion
in our patient. Although the response to treatment in the present case was excellent,
the great intensity of the eczematous local cutaneous reaction is indicative that this
way of administration should be used carefully as an alternative to systemic MA
treatment, when previous cutaneous hypersensitivity is detected.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p id="para11">This study was supported by IPEC/FIOCRUZ.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aste</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferreli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Biggio</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Intralesional treatment of cutaneous leishmaniasis with
meglumine antimoniate</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>138</volume>
          <fpage>370</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="pmid">9602904</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mauel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of protective immunity in experimental
cutaneous leishmaniasis of the guinea-pig. III. Inhibition of leishmanial lesion
in the guinea-pig by delayed hypersensitivity reaction to unrelated
antigens</article-title>
          <source>Clin Exp Immunol</source>
          <year>1977</year>
          <volume>29</volume>
          <fpage>320</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">908177</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>C&#xF3;rdoba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gandolfo Cano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aguado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huerta-Brogera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez-Mor&#xE1;n</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Delayed allergic skin reactions due to intralesional
meglumine antimoniate therapy for cutaneous leishmaniasis</article-title>
          <source>Allergy</source>
          <year>2012</year>
          <volume>67</volume>
          <fpage>1609</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">23067046</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwok</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Gibbs</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Abbott</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Topical treatments for cutaneous warts</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2012</year>
          <volume>9</volume>
          <elocation-id/>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>MP</given-names>
              <suffix>Neto</suffix>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>da Costa</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Pirmez</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Intralesional therapy of American cutaneous
leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of
<italic>Leishmania (V.) braziliensis</italic> transmission</article-title>
          <source>Int J Dermatol</source>
          <year>1997</year>
          <volume>36</volume>
          <fpage>463</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">9248897</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasconcellos</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Schubach</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Azeredo-Coutinho</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>FC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intralesional meglumine antimoniate for treatment of
cutaneous leishmaniasis patients with contraindication to systemic therapy from
Rio de Janeiro (2000 to 2006)</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>2012</year>
          <volume>87</volume>
          <fpage>257</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">22855754</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <article-title>Control of the leishmaniases: report of a meeting of the
WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March
2010</article-title>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>WHO</publisher-name>
          <year>2010</year>
          <source>(WHO Technical Report Series</source>
          <comment>no. 949)</comment>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
